Dysfunctional high-density lipoprotein in patients on chronic hemodialysis

Journal of the American College of Cardiology

Volumn 60, Issue 23, 2012, Pages 2372-2379

  Yamamoto, Suguru ^a   Yancey, Patricia G ^a   Ikizler, T Alp ^a   Jerome, W Gray ^a   Kaseda, Ryohei ^a   Cox, Brian ^b   Bian, Aihua ^a   Shintani, Ayumi ^a   Fogo, Agnes B ^a   Linton, MacRae F ^a,b   Fazio, Sergio ^a   Kon, Valentina ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; kidney; lipoprotein; statin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL TRANSPORTER; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL ACTIVITY; CELL LEVEL; CHEMOTAXIS; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE RESPONSE; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HUMAN; HYPOALPHALIPOPROTEINEMIA; IN VITRO STUDY; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MACROPHAGE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN TARGETING; RISK ASSESSMENT; TREATMENT RESPONSE;

ATHEROSCLEROSIS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS;

EID: 84870537873     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.09.013     Document Type: Article

References (43)

1. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
2. P. Muntner, J. He, B.C. Astor, A.R. Folsom, J. Coresh Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities study J Am Soc Nephrol 16 2005 529 538 (Pubitemid 41725151)
3. R.N. Foley, P.S. Parfrey, M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal disease Am J Kidney Dis 32 1998 S112 S119
4. M.G. Shlipak, L.F. Fried, M. Cushman Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors JAMA 293 2005 1737 1745
5. U. Baber, J.A. de Lemos, A. Khera Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort Kidney Int 73 2008 615 621 (Pubitemid 351264109)
6. N.I. Parikh, S.J. Hwang, M.G. Larson, J.B. Meigs, D. Levy, C.S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control Arch Intern Med 166 2006 1884 1891 (Pubitemid 44455172)
7. C. Wanner, V. Krane, W. Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
8. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
9. SHARP Collaborative Group Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Am Heart J 160 2010 785 794 e10
10. C. Baigent, M.J. Landray, C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
11. S. Lewington, G. Whitlock, R. Clarke Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 370 2007 1829 1839
12. P. Barter, A.M. Gotto, J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
13. A.R. Sharrett, C.M. Ballantyne, S.A. Coady Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study Circulation 104 2001 1108 1113 (Pubitemid 32830392)
14. M. Holzer, R. Birner-Gruenberger, T. Stojakovic Uremia alters HDL composition and function J Am Soc Nephrol 22 2011 1631 1641
15. P.G. Yancey, R.W. St. Clair Cholesterol efflux is defective in macrophages from atherosclerosis-susceptible White Carneau pigeons relative to resistant show racer pigeons Arterioscler Thromb 12 1992 1291 1304
16. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100 (Pubitemid 44878620)
17. A.R. Tall, L. Yvan-Charvet, N. Terasaka, T. Pagler, N. Wang HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab 7 2008 365 375 (Pubitemid 351598023)
18. A.V. Khera, M. Cuchel, M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
19. K. Kalantar-Zadeh, J.D. Kopple, N. Kamranpour, A.M. Fogelman, M. Navab HDL-inflammatory index correlates with poor outcome in hemodialysis patients Kidney Int 72 2007 1149 1156 (Pubitemid 47609043)
20. A. Hung, L. Pupim, C. Yu Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization Hemodial Int 12 2008 236 243 (Pubitemid 351494279)
21. W.G. Jerome, B.E. Cox, E.E. Griffin, J.C. Ullery Lysosomal cholesterol accumulation inhibits subsequent hydrolysis of lipoprotein cholesteryl ester Microsc Microanal 14 2008 138 149 (Pubitemid 351365325)
22. J.J. Klansek, P. Yancey, R.W. St. Clair, R.T. Fischer, W.J. Johnson, J.M. Glick Cholesterol quantitation by GLC: artifactual formation of short-chain steryl esters J Lipid Res 36 1995 2261 2266
23. P.G. Yancey, W.G. Jerome Lysosomal cholesterol derived from mildly oxidized low density lipoprotein is resistant to efflux J Lipid Res 42 2001 317 327 (Pubitemid 32270054)
24. W.D. Dupont Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data 2002 Cambridge University Press Cambridge, United Kingdom
25. B.O. Eriksen, O.C. Ingebretsen The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age Kidney Int 69 2006 375 382 (Pubitemid 43323090)
26. P.H. Groop, M.C. Thomas, J.L. Moran The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes Diabetes 58 2009 1651 1658
27. T.J. Orchard, A.M. Secrest, R.G. Miller, T. Costacou In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications study Diabetologia 53 2010 2312 2319
28. R.D. Kilpatrick, C.J. McAllister, C.P. Kovesdy, S.F. Derose, J.D. Kopple, K. Kalantar-Zadeh Association between serum lipids and survival in hemodialysis patients and impact of race J Am Soc Nephrol 18 2007 293 303 (Pubitemid 46053442)
29. M. Briel, I. Ferreira-Gonzalez, J.J. You Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92
30. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
31. B.J. Ansell, M. Navab, S. Hama Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756 (Pubitemid 37498976)
32. P.M. Ridker, E. Danielson, F.A. Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
33. T.A. Pagler, M. Wang, M. Mondal Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling Circ Res 108 2011 194 200
34. C.A. Bursill, M.L. Castro, D.T. Beattie High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo Arterioscler Thromb Vasc Biol 30 2010 1773 1778
35. K.D. Navab, O. Elboudwarej, M. Gharif Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease Curr Pharm Des 17 2011 17 20
36. O. Phan, O. Ivanovski, T. Nguyen-Khoa Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice Circulation 112 2005 2875 2882 (Pubitemid 41641683)
37. S. Iimori, Y. Mori, W. Akita Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study Clin Exp Nephrol 2012 May 12 [Epub ahead of print]
38. B. Shao, S. Pennathur, I. Pagani Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway J Biol Chem 285 2010 18473 18484
39. B. Shao, C. Tang, J.W. Heinecke, J.F. Oram Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export J Lipid Res 51 2010 1849 1858
40. A. Terrier-Lenglet, A. Nollet, S. Liabeuf Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease [in French] Nephrol Ther 7 2011 219 224
41. H. Moradi, M.V. Pahl, R. Elahimehr, N.D. Vaziri Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease Transl Res 153 2009 77 85
42. T. Weichhart, C. Kopecky, M. Kubicek Serum amyloid A in uremic HDL promotes inflammation J Am Soc Nephrol 23 2012 934 947
43. M. Tolle, T. Huang, M. Schuchardt High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A Cardiovasc Res 94 2012 154 162